Taking inventory: Antibacterial agents currently at or beyond Phase 1

Current Opinion in Microbiology

Volumn 7, Issue 5, 2004, Pages 466-476

  Bush, Karen ^a   MacIelag, Mark ^a   Weidner Wells, Michele ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; A 40926; A 82846 B; ANTIINFECTIVE AGENT; BI K 0376; BIK 0376; CEFALEXIN; CEFEPIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; CS 023; DALBAVANCIN; DIHYDROFOLATE REDUCTASE INHIBITOR; DORIPENEM; GENTAMICIN; ICLAPRIM; IMIPENEM; ISEGANAN; MBI 594 AN; MEROPENEM; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; ORITAVANCIN; PEXIGANAN; RAMOPLANIN; RANBEZOLID; RWJ 442831; SARALASIN; SULFONAMIDE; T 91825; TAK 599; TEICOPLANIN; TELAVANCIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; WCK 771;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL CELL WALL; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CATHETER INFECTION; CLINICAL TRIAL; CYSTIC FIBROSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SAFETY; DRUG TISSUE LEVEL; GLYCOSYLATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PHLEBITIS; PNEUMONIA; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CLINICAL TRIALS; DRUG EVALUATION; HUMANS;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; THIA;

EID: 4644303468     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2004.08.013     Document Type: Review

References (74)

1. S.J. Projan Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6 2003 427 430
2. S.J. Projan, and P.J. Youngman Antimicrobials: new solutions badly needed Curr Opin Microbiol 5 2002 463 465
3. Anonymous Doripenem: S 4661 Drugs R D 4 2003 363 365
4. S. Mushtaq, Y. Ge, and D.M. Livermore Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases Antimicrob Agents Chemother 48 2004 1313 1319
5. Y. Ge, M.A. Wikler, D.F. Sahm, R.S. Blosser-Middleton, and J.A. Karlowsky In vitro antimicrobial activity of doripenem, a new carbapenem Antimicrob Agents Chemother 48 2004 1384 1396 This paper provides an extensive in vitro susceptibility profile for doripenem, with MIC data for 281 Gram-negative and 434 Gram-positive clinical isolates.
6. M. Tsuji, Y. Ishii, A. Ohno, S. Miyazaki, and K. Yamaguchi In vitro and in vivo antibacterial activities of S-4661, a new carbapenem Antimicrob Agents Chemother 42 1998 94 99
7. N. Masuda, E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa Antimicrob Agents Chemother 44 2000 3322 3327
8. I. Kawamoto, Y. Shimoji, O. Kanno, K. Kojima, K. Ishikawa, E. Matsuyama, Y. Ashida, T. Shibayama, T. Fukuoka, and S. Ohya Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. [erratum appears in J Antibiot (Tokyo). 2003 Aug;56(8):C3] J Antibiot (Tokyo) 56 2003 565 579
9. P. Hebeisen, I. Heinze-Krauss, P. Angehrn, P. Hohl, M.G. Page, and R.L. Then In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci Antimicrob Agents Chemother 45 2001 825 836
10. B. Bozdogan, D. Esel, C. Whitener, F.A. Browne, and P.C. Appelbaum Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center J Antimicrob Chemother 52 2003 864 868 This paper describes the in vitro susceptibility of several classes of antibacterial agents against a vancomycin-resistant Staphylococcus aureus strain. WCK-771 was shown to be active against the strain, whereas commercially available fluoroquinolones were not.
11. L.M. Deshpande, and R.N. Jones Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci Clin Microbiol Infect 9 2003 1120 1124
12. N.C. Issa, M.S. Rouse, K.E. Piper, W.R. Wilson, J.M. Steckelberg, and R. Patel In vitro activity of BAL9141 against clinical isolates of Gram-negative bacteria Diagn Microbiol Infect Dis 48 2004 73 75
13. E. Azoulay-Dupuis, J.P. Bedos, J. Mohler, A. Schmitt-Hoffmann, M. Schleimer, and S. Shapiro Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia Antimicrob Agents Chemother 48 2004 1105 1111 Favorable pharmacodynamic parameters are established in a mouse pneumococcal infection model, showing that BAL9141 requires a shorter time above MIC than ceftriaxone for efficacy.
14. RWJ-442831 (2004). IDdb3 database report, vol. 2004.
15. T. Ishikawa, N. Matsunaga, H. Tawada, N. Kuroda, Y. Nakayama, Y. Ishibashi, M. Tomimoto, Y. Ikeda, Y. Tagawa, and Y. Iizawa TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties Bioorg Med Chem 11 2003 2427 2437
16. Masciadri, R. (1997). Preparation of 5-(2,4-diaminopyrimidin-5-ylmethyl)- 2H-1-benzopyranes as antibacterials. WO 9720839, F. Hoffmann-La Roche Ag, Switz.
17. Arpida Announces Positive Phase II: Clinical Results with Novel Antibiotic Iclaprim. December 9, 2003, Arpida Company Web Site, URL: http://www.arpida.ch/NewFiles/pressoverview.html.
18. P. Schneider, S. Hawser, and K. Islam Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria Bioorg Med Chem Lett 13 2003 4217 4221
19. L.A. Sorbera, J. Castaner, and X. Rabasseda Iclaprim: antibacterial dihydrofolate reductase inhibitor Drugs of the Future 29 2004 220 225 This current review gives an excellent overview of the synthesis, antimicrobial activity, pharmacokinetics and clinical studies of iclaprim.
20. J.M. Streit, T.R. Fritsche, H.S. Sader, and R.N. Jones Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates Diagn Microbiol Infect Dis 48 2004 137 143
21. D. Jabes, G. Candiani, G. Romano, C. Brunati, S. Riva, and M. Cavaleri Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model Antimicrob Agents Chemother 48 2004 1118 1123
22. A. Lefort, J. Pavie, L. Garry, F. Chau, and B. Fantin Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin Antimicrob Agents Chemother 48 2004 1061 1064
23. A. Leighton, A.B. Gottlieb, M.B. Dorr, D. Jabes, G. Mosconi, C. VanSaders, E.J. Mroszczak, K.C. Campbell, and E. Kelly Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers Antimicrob Agents Chemother 48 2004 940 945
24. E. Seltzer, M.B. Dorr, B.P. Goldstein, M. Perry, J.A. Dowell, and T. Henkel Once-weekly dalbavancin versus standard-of-care antimicrobial regimes for treatment of skin and soft-tissue infections Clin Infect Dis 37 2003 1298 1303 An account of the efficacy of dalbavancin administered as two doses a week apart in the treatment of complicated skin and soft tissue infections.
25. Seltzer E, Wible M, Goldstein BP, Dorr MB, Henkel TJ, Darouiche R et al.: Efficacy and safety of once-weekly dalbavancin vs vancomycin in catheter-related bloodstream infections. In 14th European Congress of Clinical Microbiology and Infectious Diseases: 2004 May 1-4; Prague, Czech Republic.
26. F. Van Bambeke, Y. Van Laethem, P. Courvalin, and M. Tulkens Paul Glycopeptide antibiotics: from conventional molecules to new derivatives Drugs 64 2004 913 936
27. N.E. Allen, and T.I. Nicas Mechanism of action of oritavancin and related glycopeptide antibiotics FEMS Microbiol Rev 26 2003 511 532
28. Loutit JS: Oritavancin current status. In 9th International Antibacterial Drug Discovery & Development Summit: 2004 March 29-30; Cherry Hill, New Jersey.
29. Fetterly GL, Ong C, Bhavnani SM, Loutit J, Porter S, Ambrose PG: Chracterization of oritavancin (ORI) pharmacokinetics (PK) in plasma and blister fluid in normal healthy volunteers. In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 2003 September 14-17; Chicago, Illinois.
30. Oritavancin: (2004). IDdb3 database report, vol. 2004.
31. Giamarellou H, O'Riordan W, Harris H, Owen S, Porter S, Loutit J: Phase 3 trial comparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI). In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 2003 September 14-17; Chicago, Illinois. A study showing that oritavancin for 3-7 days was as effective and better tolerated than 10-14 days of vancomycin/cephalexin in complicated skin and skin structure infections.
32. InterMune Updates Timing of Oritavancin NDA Submission: November 21, 2003. Intermune Company Web Site, URL: http://www.corporateir.net/ireye/ir_site. zhtml?ticker=ITMN&script=460&layout=-6&item_id=472321.
33. Debabov DV, Pace J, Nodwell M, Trapp S, Campbell R, Karr D et al.: TD-6424, a novel rapidly bactericidal concentration-dependent antibiotic, acts through a unique dual mode of action. In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 2003 September 14-17; Chicago, Illinois.
34. Barriere SL: Telavancin: a rapidly bactericidal agent with multiple mechanisms of action against drug-resistant Gram-positive pathogens. In 9th International Antibacterial Drug Discovery & Development Summit: 2004 March 29-30; Cherry Hill, New Jersey.
35. A. King, I. Phillips, and K. Kaniga Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria J Antimicrob Chemother 53 2004 797 803
36. J.L. Pace, K. Krause, D. Johnston, D. Debabov, T. Wu, L. Farrington, C. Lane, D.L. Higgins, B. Christensen, J.K. Judice, and K. Kaniga In vitro activity of TD-6424 against Staphylococcus aureus Antimicrob Agents Chemother 47 2003 3602 3604
37. Kaniga K, Johnston D, Wu T, Debabov D, Krause K, Pace JL et al.: Effect of human serum on time-kill curves, minimum inhibitory and bactericidal concentrations of TD-6424 against staphylococci and enterococci. In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 2003 September 14-17; Chicago, Illinois.
38. Barriere S, Shaw JP, Seroogy J, Spencer E, Kitt M: Pharmacokinetics (PK) & safety of a new antibacterial, TD-6424 (TD), in healthy subjects. In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 2003 September 14-17; Chicago, Illinois.
39. J.K. Judice, and J.L. Pace Semi-synthetic glycopeptide antibacterials Bioorg Med Chem Lett 13 2003 4165 4168 A description of the studies leading to the discovery of telavancin (TD-6424) and a report of the preliminary pharmacokinetics data in human volunteers.
40. Ling L, Puyang X, Moir DT, Sinclair A, Warner M, Woodford N et al.: In vitro activity of ramoplanin against multidrug-resistant staphylococci and enterococci. In 41st Annual Meeting of the Infectious Diseases Society of America: 2003 October 9-12; San Diego, California.
41. D.M. Citron, C.V. Merriam, K.L. Tyrrell, Y.A. Warren, H. Fernandez, and Goldstein EJC In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria Antimicrob Agents Chemother 47 2003 2334 2338 A report of the potent in vitro activity of ramoplanin against Clostridium difficile and other Gram-positive enteric anaerobes.
42. Leach T, Packman J, Blosser-Middleton RS, Labaudiniere R: In vitro activity of ramoplanin (RAMO) against vancomycin-resistant enterococci (VRE) with respect to van genotype. In 41st Annual Meeting of the Infectious Diseases Society of America: 2003 October 9-12; San Diego, California.
43. Y. Hu, J.S. Helm, L. Chen, X.-Y. Ye, and S. Walker Ramoplanin inhibits bacterial transglycosylases by binding as a dimer to lipid II J Am Chem Soc 125 2003 8736 8737
44. P. Cudic, J.K. Kranz, D.C. Behenna, R.G. Kruger, H. Tadesse, A.J. Wand, Y.I. Veklich, J.W. Weisel, and D.G. McCafferty Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation Proc Natl Acad Sci USA 99 2002 7384 7389
45. Parenti F, Candiani G, Ciabatti R, Cavaleri M: (2000). Ramoplanin injectable formulations. EP976394, Biosearch Italia S.p.A., Italy.
46. FDA Grants Fast Track Status to Genome Therapeutics' Ramoplanin for Treatment of: C. difficile-Associated Diarrhea, February 18, 2004. Oscient Pharmaceuticals Company Web Site, URL: http://investors.oscient.com/phoenix. zhtml?c=97238&p=irol-newsArticle&ID=496298&highlight=.
47. A. Rattan RBx-7644: ranbezolid hydrochloride Drugs of the Future 28 2003 1070 1077 This article incorporates much of the microbiological and pharmacokinetic data that has been presented at the last several ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy) meetings. This is one of the few publications on ranbezolid.
48. Ranbaxy Files IND: Application in India for Intravenous use of Antibacterial Oxazolidinone. July 11, 2002. Ranbaxy Company Web site, URL: http://www.ranbaxy.com/newsroom/pressrelease_det.asp?sno=80.
49. FDA Grants Fast Track Designation for IntraBiotics' Iseganan: September 5, 2003, IntraBiotics Pharmaceuticals Company Web Site, URL: http://shareholder.com/intrabiotics/ReleaseDetail.cfm?ReleaseID=117446.
50. F.J. Giles, R. Redman, S. Yazji, and L. Bellm Iseganan HCl: a novel antimicrobial agent Expert Opin Investig Drugs 11 2002 1161 1170 A comprehensive review of pre-clinical and clinical studies of iseganan.
51. A. Trotti, A. Garden, P. Warde, P. Symonds, C. Langer, R. Redman, T.F. Pajak, T.R. Fleming, M. Henke, and J. Bourhis A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy Int J Radiat Oncol Biol Phys 58 2004 674 681
52. F.J. Giles, R. Rodriguez, D. Weisdorf, J.R. Wingard, P.J. Martin, T.R. Fleming, S.L. Goldberg, E.J. Anaissie, B.J. Bolwell, and N.J. Chao A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy Leuk Res 28 2004 559 565
53. D.M. Rothstein, P. Spacciapoli, L.T. Tran, T. Xu, F.D. Roberts, M. Dalla Serra, D.K. Buxton, F.G. Oppenheim, and P. Friden Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5 Antimicrob Agents Chemother 45 2001 1367 1373
54. U.S. Sajjan, L.T. Tran, N. Sole, C. Rovaldi, A. Akiyama, P.M. Friden, J.F. Forstner, and D.M. Rothstein P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients Antimicrob Agents Chemother 45 2001 3437 3444
55. P-113 (2004). IDdb3 database report, vol. 2004.
56. Z. Yuan, J. Trias, and R.J. White Deformylase as a novel antibacterial target Drug Discov Today 6 2001 954 961
57. R.N. Jones, G.J. Moet, H.S. Sader, and T.R. Fritsche Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates J Antimicrob Chemother 53 2004 804 807
58. Lunec A: IDDB Meeting Report. In Superbugs and Superdrugs - SMI's Sixth Annual Conference: A Focus on Antibacterials (T. Scientific, ed.): April 2004; London, UK.
59. N. Shetty, and A.P.R. Wilson Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus J Antimicrob Chemother 46 2000 633 637
60. R.S. Dawe, S.H. Ibbotson, J.B. Sanderson, E.M. Thomson, and J. Ferguson A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity Br J Dermatol 149 2003 1232 1241
61. R. Frechette T-3811 Toyama/Bristol-Myers Squibb Current Opinion in Investigational Drugs (PharmaPress Ltd) 2 2001 1706 1711
62. K. Bush, M. Macielag, and J. Clancy 'Superbugs'. New antibacterials in the pipeline Emerging Drugs 5 2000 347 365
63. D. Abbanat, M. Macielag, and K. Bush Novel antibacterial agents for the treatment of serious Gram-positive infections Expert Opin Investig Drugs 12 2003 379 399
64. Toyama and Schering-Plough execute license agreement for Garenoxacin quinolone antibiotic. June 22, 2004. Schering-Plough Press Release, Schering-Plough website URL: http://www.schplough.com/schering_plough/news/ release.jsp?releaseID=583583.
65. Deshpande PK, Desai VN, Bhavsar SV, Charurvedu NC, Ghalsasi SA, Aher S et al.: WCK 771-A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin intermediate Staphylococcus aureus (VISA). In 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): 2003 September 14-17; Chicago, Illinois.
66. P.E. Sum, F.W. Sum, and S.J. Projan Recent developments in tetracycline antibiotics Curr Pharm Des 4 1998 119 132
67. Tigecycline: (2004). IDdb3 database report, vol. 2004.
68. G.G. Zhanel, K. Homenuik, K. Nichol, A. Noreddin, L. Vercaigne, J. Embil, A. Gin, J.A. Karlowsky, and D.J. Hoban The glycylcyclines: a comparative review with the tetracyclines Drugs 64 2004 63 88 This review article provides an excellent summary of the in vitro and in vivo, pharmacological and clinical data for tigecycline.
69. D. Milatovic, F.J. Schmitz, J. Verhoef, and A.C. Fluit Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates Antimicrob Agents Chemother 47 2003 400 404
70. C.R. Dean, M.A. Visalli, S.J. Projan, P.E. Sum, and P.A. Bradford Efflux-mediated resistance to tigecycline GAR-936 in Pseudomonas aeruginosa PAO1 Antimicrob Agents Chemother 47 2003 972 978
71. M.A. Visalli, E. Murphy, S.J. Projan, and P.A. Bradford AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis Antimicrob Agents Chemother 47 2003 665 669
72. Positive phase II results for Basilea's novel first-in-class antibiotic. March 3, 2004. Basilea Pharmaceutica website URL: http://www.basilea.com/en/ news.html?xmlURL=http://cws.huginonline.com/B/134390/PR/200403/936535.xml.
73. Additional FDA fast track designation for Basilea's novel first-in-class antibiotic. June 16, 2004. Basilea Pharmaceutica website URL: http://www.basilea.com/en/news.html?xmlURL=http://cws.huginonline.com/B/134390/ PR/200406/949205.xml.
74. IntraBiotics stopped iseganan trial in ventilator-associated pneumonia for safety reasons. June 23, 2004, IntraBiotics Pharmaceuticals Company Web Site, URL: http://shareholder.com/intrabiotics/ReleaseDetail.cfm?ReleaseID= 137662.